Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Trial details
- Registry ID
- NCT06282575
- Drugs studied
- Cisplatin, Durvalumab, Gemcitabine, Pembrolizumab and 1 more